British stomach cancer group trial IV: A randomised trial of cimetidine treatment in gastric cancer

The study of anthropometric and bioimpedance parameters in assessing the physical development of patients helps to clarify the diagnosis, predict the course of the disease, and identify groups of increased risk for the development of the disease. The aim of this study was to identify anthropometric and bioimpedance metrics in patients with stomach cancer. Anthropometric and bioimpedansometric examination of 250 patients with verified gastric cancer, 123 men and 127 women was carried out. As a comparison group, the study used the results of anthropometric and bioimpedance measurements of healthy 221 men and 267 women of the same age in the Krasnoyarsk Territory population. To determine a set of anthropometric and bioimpedansometric variables, allowing to classify the observed people depending on the presence (group of patients with gastric cancer) or the absence of stomach cancer (group of healthy people), the method of discriminant analysis was applied. To test the hypothesis about the homogeneity of the covariance matrices of the compared groups, the multidimensional Box M-criterion was used. The statistical significance of the power of the discriminant function was assessed using the Wilks test. For each discriminant function, the role of its components was assessed by comparing the matrices of total variances and covariances using the F-test. Shoulder diameter for men and women, chest diameter (transverse size) for men and women, waist circumference for men, waist / hip ratio for men and women; lean mass in men, total fluid in men, fat mass in women, phase angle in men and women are statistically significantly different in the observed groups. The developed discriminant models with an accuracy of 75-77% suggest the presence of gastric cancer in patients and can be used in clinical practice at the stage of general medical examination in groups at increased risk of developing the disease.

Download Full-text

DETERMINATION OF P53 GENE CODON 72 POLYMORPHISMS IN PATIENTS WITH GASTRIC CANCER

Journal of Medicine and Pharmacy ◽

10.34071/jmp.2013.2.2 ◽

2013 ◽

pp. 11-17

Author(s):

Thi Tuy Ha Nguyen ◽

Thi Minh Thi Ha

Keyword(s):

Gastric Cancer ◽

Cancer Patients ◽

P53 Gene ◽

Diffuse Gastric Cancer ◽

Codon 72 ◽

Cancer Group ◽

Pcr Rflp ◽

Gastric Cancer Patients ◽

The Relationship

Background: The role of p53 gene in the gastric cancer is still controversial. This study is aimed at determining the rate of the p53 gene codon 72 polymorphisms in gastric cancer patients and evaluating the relationship between these polymorphisms and endoscopic and histopathological features of gastric cancer. Patients and methods: Sixty eight patients with gastric cancer (cases) and one hundred and thirty six patients without gastric cancer (controls) were enrolled. p53 gene codon 72 polymorphisms were determined by PCR-RFLP technique with DNA extracted from samples of gastric tissue. Results: In the group of gastric cancer, Arginine/Argnine, Arginine/Proline and Proline/Proline genotypes were found in 29.4%, 42.7% and 27.9%, respectively. The differences of rates were not statistically significant between cases and controls (p > 0,05). In males, the Proline/Proline genotype was found in 38.1% in patients with gastric cancer and more frequent in patients without gastric cancer (15.7%, p = 0,01). An analysis of ROC curve showed that the cut-off was the age of 52 in the Proline/Proline genotype, but it was 65 years old in the Arginine/Proline genotype. The Proline/Proline genotype was found in 41.9% in Borrmann III/IV gastric cancer, this rate was higher than Borrmann I/II gastric cancer (16.2%, p = 0.037) and also higher than controls (18.4%, p = 0,01). The rate of Proline/Proline genotype was 41.7% in the diffuse gastric cancer, it was higher than in controls (p = 0,023). Conclusion: No significative difference of rate was found in genotypes between gastric cancer group and controls. However, there was the relationship between Proline/Proline genotype and gastric cancer in males, Borrmann types of gastric cancer, the diffuse gastric cancer. Key words: polymorphism, codon 72, p53 gene, PCR - RFLP, gastric cancer.

Download Full-text

BIOPSY OF THE SIGNALING LYMPH NODES IN GASTRIC CANCER - CURRENT STATUS OF THE PROBLEM AND PROSPECTS

Problems in oncology ◽

10.37469/0507-3758-2018-64-3-335-344 ◽

2018 ◽

Vol 64 (3) ◽

pp. 335-344

Author(s):

Aleksey Karachun ◽

Yuriy Pelipas ◽

Oleg Tkachenko ◽

D. Asadchaya

Keyword(s):

Gastric Cancer ◽

Lymph Node ◽

Sentinel Lymph Node ◽

Lymph Nodes ◽

Stomach Cancer ◽

Current Status ◽

Regional Lymph Nodes ◽

Systematic Analysis ◽

Tumor Spread ◽

Special Value

The concept of biopsy of sentinel lymph node as the first lymph node in the pathway of lymphogenous tumor spread has been actively discussed over the past decades and has already taken its rightful place in breast and melanoma surgery. The goal of this method is to exclude vain lymphadenectomy in patients without solid tumor metastases in regional lymph nodes. In the era of minimally invasive and organ-saving operations interventions it seems obvious an idea to introduce a biopsy of sentinel lymph node in surgery of early gastric cancer. Meanwhile the complexity of lymphatic system of the stomach and the presence of so-called skip metastases are factors limiting the introduction of a biopsy of sentinel lymph node in stomach cancer. This article presents a systematic analysis of biopsy technology of signaling lymph node as well as its safety and oncological adequacy. Based on literature data it seems to us that the special value of biopsy of sentinel lymph nodes in the future will be in the selection of personalized surgical tactics for stomach cancer.

Download Full-text

Exploring the interactions between Hp infection and other risk factors of gastric cancer: a pooled analysis in the Stomach cancer Pooling ( StoP ) Project

International Journal of Cancer ◽

10.1002/ijc.33678 ◽

2021 ◽

Author(s):

Giulia Collatuzzo ◽

Claudio Pelucchi ◽

Eva Negri ◽

Lizbeth López‐Carrillo ◽

Shoichiro Tsugane ◽

...

Keyword(s):

Risk Factors ◽

Gastric Cancer ◽

Stomach Cancer ◽

Pooled Analysis

Download Full-text

A randomized trial comparing whole abdominal radiotherapy with chemotherapy following cisplatinum cytoreduction in epithelial ovarian cancer. West midlands ovarian cancer group trial II

Clinical Oncology ◽

10.1016/s0936-6555(05)80210-9 ◽

1990 ◽

Vol 2 (1) ◽

pp. 4-9 ◽

Cited By ~ 33

Author(s):

F. Lawton ◽

D. Luesley ◽

G. Blackledge ◽

C. Hilton ◽

K. Kelly ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Randomized Trial ◽

Cancer Group ◽

West Midlands ◽

Abdominal Radiotherapy ◽

Group Trial

Download Full-text

Expression and Clinical Significance of Serum Exosomal miR-375 in Patients with Gastric Cancer

Tobacco Regulatory Science ◽

10.18001/trs.7.5.1.162 ◽

2021 ◽

Vol 7 (5) ◽

pp. 3896-3904

Author(s):

Daoting Deng ◽

Hong Zhang ◽

Junxi Liu ◽

Lina Ma ◽

Xinrui Lei ◽

...

Keyword(s):

Gastric Cancer ◽

Cancer Patients ◽

Cox Regression ◽

Prognostic Significance ◽

Cox Regression Analysis ◽

Healthy Group ◽

Cancer Group ◽

Kaplan Meier ◽

Gastric Cancer Patients ◽

Gastric Cancer Group

To explore exosomal miR-375 expression in gastric cancer patients and its relationship with patient prognosis. A total of 53 patients diagnosed with gastric cancer in our hospital from May 2014 to May 2016 were included as the gastric cancer group, and 46 healthy women who came to our hospital for physical examination during the same period were enrolled as the healthy group. Exosomal miR-375 expression level was detected using qRT-PCR, and the diagnostic performance and prognostic significance of exosomal miR-375 in gastric cancer were explored. The gastric cancer group showed increased exosomal miR-375 expression than the healthy group (P< 0.05); Kaplan-Meier survival analysis exhibited that serum exosomal miR-375 has an AUC of 0.778, sensitivity of 69.57%, and specificity of 75.47%, whereas Cox regression analysis showed that the miR-375 expression in exosomes was an independent risk factor affecting the prognosis of gastric cancer patients (P< 0.05). Patient with gastric cancer showed upregulated miR-375 expression in serum exosomes. Serum exosomal miR-375 was found to has positive sensitivity and specificity in the diagnosis of gastric cancer, which may be associated with poor prognosis of gastric cancer patients.

Download Full-text